Global Kinetics Corporation with researchers from the Florey Neuroscience Institute, presents the Personal KinetiGraph™ (PKG™) movement recording. The PKG™ Data Logger is a wrist worn device, that looks like a wristwatch, that automatically records movement data to assist Doctors in their diagnosis and treatment of the symptoms of movement disorders.
The Personal KinetiGraph™ (PKG™) movement recording
The PKG™ Data Logger is worn like a wrist watch and features a vibrating reminder of when patients should register that they have taken their levodopa medication as prescribed by their Doctor. It is worn continuously over 6 to 10 days in the home environment during the activities of daily living, during which time it uses an accelerometer to automatically record movement data.
This data enables a report to be created for the Neurologist showing the kinematics of symptoms of movement disorders and the timing of levodopa medication for compliance monitoring.
Having an objective record of the movement symptoms assists the Doctor’s understanding of the nature and progression of the disease. On assessment of the movement recording the Doctor may change the treatment: type, amount or timing of the medication, or recommend an advanced therapy, such as deep brain stimulation.
The Personal KinetiGraph™ - cutting edge technology being used by Doctors to help improve the quality of life for sufferers of movement disorders.
The PKG™ is cleared by the FDA for sale in the United States.
About Movement Disorders, Such as Parkinson's Disease
There is a broad range of movement disorders, with Parkinson’s Disease being the most prevalent. Globally, there are over 6 million people who have Parkinson’s Disease. 10% of people who are diagnosed with Parkinson’s Disease are younger than 50 years.
Parkinson’s Disease is a progressive disorder of the frontal lobe of the brain, the part of the brain that controls impulsive and non-impulsive movement. People with Parkinson’s have less dopamine, a chemical ‘messenger’ in the brain that sends messages to the body on how control movement.
The main motor (or movement) related symptoms of Parkinson’s Disease are are bradykinesia, rigidity, tremors, postural instability. Other non-movement symptoms may be experienced such as speech and swallowing difficulties, cognitive impairment or behavioural change and sleep disturbance.
The most common treatment for Parkinson’s disease, levodopa, aims to increase the amount of dopamine in the brain. Treatment doesn’t cure the disease, but can improve symptoms to enable people with Parkinson’s to live independently and enjoy a better quality of life. Parkinson’s disease is a challenging illness and each person may experience different symptoms with varying severity.
Other Movement Disorders include Parkinsonian Tremor, Restless Legs Syndrome, Dystonia, Huntington’s disease, Progressive Supranuclear Palsy (PSP) or Wilson’s Disease.
News and Reviews
CE Mark awarded to second generation PKG™ system
Global Kinetics Corporation has secured CE marking on its second generation Personal KinetiGraph™ (PKG™) System, indicating that the product complies with EU health and safety requirements and legislation.
The system has also recently received clearance from the US Food and Drug Administration (FDA) and has been introduced in both the USA and Australia, where it received avid support from patients.
The CE marking of the new technology underpins GKC’s aggressive expansion into new product and service offerings to meet the needs of the Parkinson’s community worldwide. It also enables us to build upon the already substantial partnerships with global pharmaceutical and device leaders in the area of Parkinson’s.
The new technology will be introduced to patients and clinicians in twelve leading European movement disorder clinics in the next two months, with a full rollout to follow thereafter.The second generation PKG™ is an important development that will deliver a new era of impact for patients around the world.
To read the full article, please click here
Global Kinetics and uMotif announce technology partnership for Parkinson’s trials
Global Kinetics Corporation and uMotif have announced a new partnership bringing together two leading proprietary products to provide a unique data capture platform for Parkinson’s research.
The combined Parkinson’s platform is based on two leading clinically validated systems for clinical trials and incorporates the PKG™ system and uMotif’s mobile and web platform for trial data capture, providing a means to measure and demonstrate the value of medications, devices and services in PD, from clinical through to commercial phases of development.
This partnership represents a significant strategic move for our company, responding to the needs of commercial sponsors for high quality data and systems to support both traditional and innovative trial designs. The GKC and uMotif Parkinson’s platform is now available globally for all phases of Parkinson’s trials.
To read the full article, please click here
Personal KinetiGraph™ featured in Swedish Parkinson Journal
The Parkinson Journal, published by the Swedish Parkinson's Disease Association, recently featured an article on the Personal KinetiGraph™.
In the article Associate Professor and neurologist Dr Nil Dizdar of the University Hospital in Linkoping, describes how the PKG™ provides an accurate assessment of the symptoms of Parkinson's which has benefits for both patients and healthcare providers. She also calls for widespread use of the technology to allow for remote assessment of patient symptomology.
To read an English excerpt from the article, please click here
To read the full article in Swedish, please click here